Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06656390 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Shanghai Allink Biotherapeutics Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 202
- Enrollment target
NCT06656390 is a Phase 1 study that is actively recruiting participants, run by Shanghai Allink Biotherapeutics Co.. The registered enrollment target is 202 participants.
The verdict
NCT06656390, a Phase 1 study, is actively recruiting participants, sponsored by Shanghai Allink Biotherapeutics Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 202 participants
- Enrollment target
Study Summary
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK201.
Interventions
- DRUG ALK201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2028-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06656390
The ClinicalTrials.gov registry entry for NCT06656390 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shanghai Allink Biotherapeutics Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALK201 is the first listed.
NCT06656390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06656390 about?
NCT06656390 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors". This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The stu...
What is the current status of trial NCT06656390?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 202 participants. The study started on 2024-10-24. Estimated completion is 2028-04-22.
What interventions are being tested in trial NCT06656390?
The interventions under investigation include: ALK201 (DRUG).
Who is sponsoring clinical trial NCT06656390?
This trial is sponsored by Shanghai Allink Biotherapeutics Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.